Treatment Plans

Important Medication Info:
FDA-approved medications such as Saxenda®, Victoza®, Wegovy®, and Ozempic® are proprietary to Novo Nordisk™, while Mounjaro® and Zepbound™ are products of Eli Lilly and Company™. This website is not affiliated with, endorsed by, or associated with these companies or their products.

Invigor Medical does not supply FDA-approved branded medications. Instead, compounded alternatives may be prescribed when clinically appropriate and legally permissible. These medications are prepared by licensed 503A pharmacies in accordance with the Federal Food, Drug, and Cosmetic Act.

Compounded drugs are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality. They may be prescribed when commercially available products are unsuitable for an individual’s medical needs, but have not been evaluated by the FDA to confirm safety or efficacy for any specific use.

Important Safety Information for GLP-1 Treatments

Compounded medications are legally prescribed under federal law but are not FDA-approved and have not undergone FDA review for safety, effectiveness, or manufacturing quality. The GLP-1 treatment available through Invigor Medical is prescribed based on an individualized medical evaluation by a licensed clinician.

WARNING: Risk of Thyroid C-Cell Tumors
In animal studies, GLP-1 receptor agonists have been associated with thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is not known whether these effects occur in humans. Inform your healthcare provider if you experience neck swelling, hoarseness, difficulty swallowing, or shortness of breath. GLP-1 treatments should not be used by individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Do not use GLP-1 treatments if:

• You or a family member have a history of MTC or MEN 2.
• You have been diagnosed with type 1 diabetes, pancreatitis, or severe gastrointestinal disease such as gastroparesis.
• You have a known allergy to GLP-1 medications or their components.
• You have a history of suicidal thoughts or behaviors.

Warnings and Precautions:

• Pancreatitis: Discontinue immediately if severe abdominal pain occurs.
• Gallbladder Disease: Gallstones and other gallbladder issues may occur; monitor for symptoms.
• Hypoglycemia: Risk may increase when combined with insulin or insulin secretagogues.
• Kidney Injury: Monitor kidney function in patients with dehydration or severe GI symptoms.
• Mood Changes: Stop use and contact your provider if you experience depression or suicidal thoughts.

Pregnancy and Reproductive Health:
GLP-1 medications may cause harm to a fetus and should not be used during pregnancy or when planning to become pregnant. Discontinue at least two months before a planned pregnancy.

Common Side Effects:
Nausea, vomiting, diarrhea, constipation, abdominal discomfort, fatigue, and headache are the most commonly reported side effects.

Drug Interactions:
GLP-1 treatments may slow gastric emptying and affect the absorption of oral medications. Consult your healthcare provider for guidance on medication timing and adjustments.